Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) fell this week. The stock lost 24% as of market close on Friday. The move comes as the S&P 500 and Nasdaq Composite both slipped slightly. Recursion ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

Recursion Pharmaceuticals has agreed to acquire the Oxford, U.K.-based artificial intelligence (AI) drug pioneer Exscientia, the companies said today, in a deal that consolidates two leaders in ...

Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

It's tiny, really: one of the linked resources in the linked lesson (this one https://www.scaler.com/topics/fibonacci-series-in-javascript/) has a small inconsistency ...

AI mania has found its way into biotech stocks. Recursion Pharmaceuticals shares have jumped some 80% on Wednesday. The biotech company said that Nvidia is investing $50 million to boost Recursion’s ...

Recursion can be accomplished in any turing complete programming language, Turing Completeness. Javascript, python and every other programming language you'll encounter in your career will be a ...